Introduction
The three subtypes of IP 3 Rs expressed in vertebrates (IP 3 R1-3) are closely related proteins and they are each regulated by both (1,4,5)IP 3 (1, Fig. 1 ) and Ca
2+
, but they differ in their sensitivity to other forms of regulation and in their subcellular and tissue distributions. 1 Extensive structure-activity studies, [4] [5] [6] [7] [8] reinforced by a highresolution structure of (1,4,5)IP 3 bound to the IP 3 -binding core of IP 3 R1 (Fig. 1A) , 9 established that the vicinal 4,5-bisphosphate moiety is essential for (1,4,5)IP 3 binding and the equatorial 6-hydroxyl and 1-phosphate confer high affinity (Fig. 1B) . All high-affinity agonists of IP 3 R have structures equivalent to these substituents. The only endogenous inositol phosphate likely to bind to IP 3 Rs under physiological conditions is (1,4,5)IP 3 , the immediate water-soluble product of phospholipase C-catalyzed hydrolysis of the membrane lipid phosphatidylinositol 4,5-bisphosphate. However, synthetic ligands of IP 3 Rs, including many inositol phosphates 7 and derivatives of adenophostins, [10] [11] [12] have provided insight into the structural determinants of IP 3 R activation. These ligands include analogs of (1,4,5)IP 3 that are resistant to degradation, 13 fluorescent analogs, 14 partial agonists, 6 and synthetic derivatives of adenophostins. 10 There are, however, no ligands of IP 3 R that distinguish effectively between IP 3 R subtypes, 5, 15, 16 and the only available antagonists have severe limitations. 17 The commonly used antagonists are heparin, 2-aminoethoxydiphenyl borate (2-APB), xestospongins and high concentrations of caffeine. The limitations of these antagonists include off-target effects, notably interactions with other Ca 2+ channels, Ca 2+ pumps, G proteins and other signalling pathways; membrane-impermeability (heparin) and, for xestospongins, an inconsistent history of effectiveness as discussed recently. 17 This study was undertaken with the aim of developing more effective antagonists of IP 3 R.
(1,3,4,6)IP 4 , which retains the essential pharmacophore of an IP 3 R agonist (Fig. 1B) , stimulates Ca 2+ release via IP 3 R, but its affinity is between 10 and 100-fold lower than that of (1,4,5)IP 3. 18-21 Some, 19, 22 though not all, 21 studies have suggested that (1, 3, 4, 6 )IP 4 may be a partial agonist, namely that it less effectively activates IP 3 R than full agonists like (1,4,5)IP 3 . It seems likely that the inverted position of the 2-OH in (1, 3, 4, 6 )IP 4 (equivalent to the 3-OH of (1,4,5)IP 3 when the structures are compared in orientations likely to reflect their interactions with IP 3 R, Fig. 1B ) is a major determinant of the reduced affinity. 5, 20 Although (1,3,4,6)IP 4 is produced endogenously from (1,3,4)IP 3 , it is unlikely to attain concentrations that regulate IP 3 Rs. 24 Nevertheless, we chose (1,3,4,6)IP 4 to attempt development of novel antagonists of IP 3 R because it and analogs in which its free hydroxyls are modified (3, 4) are meso compounds that make synthesis more straightforward, and we had initially supposed that (1,3,4,6)IP 4 might have reduced efficacy. 19, 22 We previously reported that dimers of inositol phosphates are high-affinity partial agonists of IP 3 R. 6 We have now developed a family of antagonists of IP 3 Rs (5-12 in Fig. 1C ) from the (1,3,4,6)IP 4 backbone by modification of its free hydroxyls and dimerization of the modified structures. Diesteric or dietheric (X = O or H 2 ) linkages of various sizes (n = 1-3) were chosen for these 5-Ohomodimers, which were synthesized by means of a diverse and versatile approach. The most useful of these ligands (8, 10 and 12) bind to IP 3 R1 with an affinity comparable to that of the best available competitive antagonist of IP 3 R, heparin, the utility of which is limited by its off-target effects.
Results and discussion

Chemistry
Synthesis of IP 4 s and IP 5 . Phosphates 2-4 were all prepared from myo-inositol (13) (Scheme 1). Thus, tetrasodium Ins(1,3,4,6)P 4 (2) was synthesized from butanedione-derived acetal 14 25 following a previously published route. 26 Pentasodium Ins(1,2,3,4,6)P 5 (4) was reached via pentol 15a and pentakis phosphate 15b. Modifications on the perphosphorylation and hydrogenolysis protocols, 26 of an inositol biscyclohexylidene acetal originated synthetic scheme, 27 were applied in order to solely obtain the pentasodium salt. The preparation of butanoate 3 involved a novel approach. Thus, acetal 14 was initially selectively protected at the C-2 position as the PMB ether to yield 16a. Masking of the remaining C-5 hydroxyl as the benzyl ether gave the fully protected derivative 16b, which was very carefully deprotected 28 upon treatment with aqueous DDQ to reach free alcohol 16c. Introduction of the required butyryl group was performed by esterification with butyric anhydride. The resulting ester (16d) was then exposed to aqueous TFA to cleave both acetals, and the corresponding tetraol (17a) was formed quantitatively. Perphosphorylation of crude 17a was accomplished using a 1H-tetrazole solution in acetonitrile and dibenzyl N,N-diisopropylphosphoramidate at ambient temperature, followed by direct oxidation of the intermediate phosphite with m-chloroperbenzoic acid at low temperature. Finally, the obtained benzyl tetrakisphosphate 17b was subjected to hydrogenolysis in ethanol/water in the presence of Pd/C and sodium bicarbonate (exactly one equivalent per phosphate group) to yield quantitatively the desired tetrasodium salt 3.
Synthesis of dimeric analogs of IP 4 and IP 5 . For the synthesis of dimers 5-12, we envisioned the retrosynthetic analysis depicted in Scheme 2. Dimers 5-12 could be reached from the corresponding polyols 18 applying sequentially perphosphorylation and global deprotection protocols. The key to obtain all these compounds, differentially substituted on C-2, from a common intermediate (19) was to introduce orthogonal protective groups (PG and PG') at an early stage of the synthesis. In this way, 19 could serve as the sole precursor for both series (2-O-butyrylated and 2-O-phosphorylated derivatives) by selective removal of PG'. Esters and ethers 19 could, in turn, be prepared by dimerization of the corresponding monomers 20 using the appropriate linkers. Since this process involved the relatively hindered secondary alcohols 20, we were keen to explore the feasibility of this approach. Finally, starting from myo-inositol (13) selective introduction of the required protective groups was expected to lead to monomers 20.
Monobenzyl ether 21 (Scheme 3) was recognized as a suitable derivative, appropriately functionalized to play the role of 20. Moreover 21 is easily accessible 25, 29, 30 from myoinositol through butanedione bisacetal 14. Direct dimerization of this compound was initially investigated using the Steglich esterification approach 31 and employing malonic (n = 1) and succinic acid (n = 2) as linkers (Scheme 3 and Table S1 in ESI). However, these apparently simple couplings were found to be complicated, under various reaction conditions tested, by the formation of acetate 22 (in the first case) and N-acylureas 24a-c (in both cases). Thus, for malonic acid reactions, the presence of DMAP seemed to solely favor the decarboxylation process, regardless of the carbodiimide (DCC or DIC) and the solvent used. 32 We could not securely determine whether this decarboxylation occurred prior to or after the first esterification. However, in other runs we isolated the Nacylureas 24a and 24b, suggesting that acetate 22 is formed from malonic monoester. Although replacing DMAP with DIPEA eliminated this problem, the only product isolated was N-acylurea 24b, in very low yield, whereas starting material was quantitatively recovered when EDC was used. On the other hand, the reactions performed in the absence of base were productive, yielding the desired dimer (23a) along with the corresponding N-acylurea (24a or 24b). The best results were obtained in the case of the DCC-promoted coupling. 34 Surprisingly, applying the same conditions (DCC in Et 2 O) for the coupling of 21 with succinic acid was unsuccessful. In order to reach dimer 23b the presence of DMAP was a crucial factor using either DCC or EDC in CH 2 Cl 2 . 34 Again, the reaction with DCC furnished an inseparable mixture of dimer 23b and Nacylurea 24c, which was subsequently resolved upon hydrogenolysis. In contrast to esters 23a,b, the synthesis of dimeric ethers 25a,b was accomplished in a more facile way.
Williamson etherifications, through the in situ formed (NaH) sodium alkoxide of 21, were initially attempted in DMF using the required diiodo-or dibromo-alkanes, but with poor results. Replacing halo-electrophiles with the more reactive ditosylates 26 35 and 27 36 and applying a protocol 37 which involved KOH as base and a more polar solvent (DMSO) furnished the desired dimers (25a,b) in a clean way and in good yields. 38 With the key intermediate dimers in our hands, we proceeded to the next steps, which involved installation of the butyryl and phosphate groups. Pd-catalyzed hydrogenolysis of 23a,b and 25a,b led to the corresponding diols 28, which were esterified upon exposure to butyric anhydride to give 29 in very good yields (Scheme 4). Both 28 and 29 were then used to reach the final targets. Thus, careful treatment of these dimers (especially in the case of 29) with aqueous TFA furnished octaols and decaols 30, in nearly quantitative yields (Scheme 4). Perphosphorylation of these crude polyols was accomplished as described for 17b (Scheme 1) to obtain the protected polyphosphates 31. The latter were debenzylated upon hydrogenolysis in the presence of sodium bicarbonate to yield the octakis and decakis phosphate salts 5-12. (Fig. 1B) . The analogs retained both the essential pharmacophore (Fig. 1B, blue) , and the 5-hydroxyl and 6-phosphate groups [equivalent to the Please do not adjust margins Please do not adjust margins 6-hydroxyl and 1-phosphate of (1,4,5)IP 3 ] that increase binding affinity (Fig. 1B, green) .
A maximally effective concentration of 2-O-butyryl-(1,3,4,6)IP 4 released a smaller fraction of the intracellular Ca 2+ stores than did (1,4,5)IP 3 ( Fig. 2B) and it bound to the IP 3 R1 with 50 ± 22-fold lower affinity than (1,4,5)IP 3 (Fig. 2C) (Fig. 1B) , but it has an axial phosphate at the 2-position [equivalent to the 3-position of (1,4,5)IP 3 ]. Others have reported that an axial phosphate at the 3-position of (1,4,5)IP 3 reduced affinity. 40 The important observation is that addition of an axial 2-phosphate to ( The activities of (1,2,3,4,6)IP 5 (4) and the dimer 6 are directly compared in Fig. 3 . Neither 4 nor 6 (100 µM) evoked Ca 2+ release, but they reduced the sensitivity of the Ca 2+ release evoked by (1,4,5)IP 3 by 2.4 ± 0.2 and 20.9 ± 0.7-fold, respectively, without affecting the maximal response or Hill coefficient. Hence the dimer 6, like the monomer 4, is a competitive antagonist, but 6 has an apparent affinity that is 8.8 ± 1.0-fold greater than 4 (Table S3 in ESI). Table S2 .
The results with 6, suggesting that a dimer of (1,3,4,5,6)IP 5 retained the lack of efficacy of (1,3,4,5,6)IP 5 while displaying improved affinity, prompted analysis of seven additional dimeric analogs of 2-O-butyryl-(1,3,4,6)IP 4 and (1,2,3,4,6)IP 5 (Fig. 1C) . None of the dimers (5-12, 100 µM) evoked Ca 2+ release, and they all significantly decreased the sensitivity to (1,4,5)IP 3 without affecting the maximal Ca 2+ release or Hill Table S3. coefficient ( Fig. 4 and Table 1 ). All of the dimers (5-12) are therefore competitive antagonists. Although 2-O-butyryl-(1,3,4,6)IP 4 is a partial agonist with a K d of 4.8 µM (Fig. 2B and Table S2 in ESI), its dimeric analogs are competitive antagonists with slightly reduced apparent affinities (K d = 15-44 µM) ( Table 1 ). The decreased affinity is consistent with evidence from analogs of (1,4,5)IP 3 , where substitution of the 6-hydroxyl (equivalent to the 5-hydroxyl of 3, through which the dimers are linked) reduced affinity. 41, 42 The 6-hydroxyl of (1,4,5)IP 3 is thought to stabilize interactions of the IP 3 -binding core. 7 However, the reduction in affinity between 3 and its dimers is modest by comparison with the 70 to 100-fold decrease for 6-deoxy-(1,4,5)IP 3 and 6-methoxy-(1,4,5)IP 3 relative to (1,4,5)IP 3 . 41, 42 Hence, dimerization of 2-Obutyryl-(1,3,4,6)IP 4 , to give 5, 7, 9 and 11, successfully reduced efficacy, but without improving affinity ( Table 1) . The antagonist, 12, is one of three dimers of (1,2,3,4,6)IP 5 (4) with equally high affinity and it shifted the EC 50 for (1,4,5)IP 3 by 19.4 ± 6.5-fold, suggesting an apparent K d of ~7 µM (Fig. 4B) . Given the similar affinities of the dimers 8, 10 and 12 (K d 7-8 µM) in functional assays (Table 1) , we examined only 12 in equilibrium competition binding experiments. The K d value for 12 determined in these experiments (7.7 µM) concurs with the results from functional analyses ( Table 1) . Fig. 4 show the effects of (1,4,5)IP3 alone or in the presence of 100 µM of each analog. Results show pEC50, ΔpEC50 (pEC ହ ୡ୭୬୲୰୭୪ -pEC ହ ୟ୬୲ୟ୭୬୧ୱ୲ ) and Hill coefficients (nH) (means ± s.e.m.) and EC50 for (1,4,5)IP3-evoked Ca 2+ release (n = 3). Kd is shown calculated from functional assays and from equilibrium competition binding experiments (n = 3). Statistical differences were determined by one-way ANOVA and Tukey's post hoc test, and refer to the results with (1,4,5)IP3 alone, *P < 0.05.
These results establish that 8, 10 and 12 are competitive antagonists of IP 3 R with low-micromolar affinity. Although modifications of the 6-hydroxyl of (1,4,5)IP 3 reduced affinity, 41, 42 dimerization through the analogous 5-hydroxyls of 3 and 4 caused more modest decreases or increases in affinity, respectively (Table 1) . That pattern is similar across the four different linkers used (Fig. 1C) . For each linker, dimers of 4 had release from permeabilized DT40-IP3R1 cells after preincubation (2 min) with the indicated dimers (5-12, 100 µM). Results are means ± s.e.m., n = 3. Summary results in Table 1. 2 to 3-fold greater affinity than dimers of 3, even though monomeric 4 has significantly lower affinity than monomeric 3 (Fig. 4 , Table 1 and Table S2 in ESI). For dimers of both 3 and 4, the shortest linker (n = 1, Fig. 1C ) less effectively increased affinity than did the longer linkers (n = 2-3) ( Table 1) .
Conclusions
There is a need for selective antagonists of IP 3 Rs. 17 HRMS spectra were used to establish identity. Esterification of malonic acid with 21. Malonic acid (280 mg, 2.69 mmol), and DCC (4.43 g, 21.5 mmol) were successively added to a solution of alcohol 21 (2.69 g, 5.39 mmol) in dry Et 2 O (50 mL). The resulting slurry was vigorously stirred under an Ar atmosphere at room temperature for 24 h, while the reaction progress was monitored by TLC. Upon completion, the solvent was removed in vacuo. The residue was triturated with Et 2 O and filtered. The solid was further washed with Et 2 O (25 mL) and the filtrates were concentrated in vacuo and the residue was purified with flash column chromatography (hexanes/EtOAc 5:1 to 2:1) to give 1.78 g (62%) of diester 23a and 510 mg (12%) of ureido derivative 24b.
Esterification of succinic acid with 21. Succinic acid (160 mg, 1.36 mmol), DMAP (133 mg, 1.1 mmol), and DCC (1.69 g, 8.2 mmol) were successively added to a solution of alcohol 21 (1.36 g, 2.72 mmol) in dry CH 2 Cl 2 (25 mL). The resulting slurry was vigorously stirred under an Ar atmosphere at room temperature for 96 h, while the reaction progress was monitored by TLC. Upon completion, the reaction mixture was washed with H 2 O (25 mL) and saturated brine (25 mL). The combined aqueous phases were back-extracted with CH 2 Cl 2 (4×50 mL), the combined organic phases were dried over Na 2 SO 4 , and the solvents were removed in vacuo. (20 mL) , and MeOH (20 mL). Diols 28 were found to be sufficiently pure and used in the next steps without any further purification.
General Procedure C: Preparation of butyrates 29. Dry Et 3 N (0.56 mL, 4 mmol) and DMAP (50 mg, 0.4 mmol) were added to a solution of diol 28 (1 mmol) in dry CH 2 Cl 2 (10 mL) under an Ar atmosphere at room temperature. Butyric anhydride (0.50 mL, 3 mmol) was added and the mixture was stirred at room temperature until the full consumption of starting material (TLC monitoring, about 24 h). The reaction mixture was diluted with CH 2 Cl 2 (20 mL) and successively washed with saturated aqueous sodium bicarbonate solution (3×10 mL) and saturated brine (10 mL). The aqueous phase was back-extracted with CH 2 Cl 2 (10 mL) and the combined organic phases were dried over Na 2 SO 4 and concentrated in vacuo. The residue was purified with flash column chromatography (hexanes/EtOAc 7:1 to 1:1) to give butyrates 29.
General Procedure D: Removal of acetal protecting groups. A 90% aqueous solution of TFA (10 mL) was added dropwsise to a solution of starting acetal (16d or 28 or 29, 1 mmol) in CH 2 Cl 2 (10 mL) at room temperature. The resulting mixture was stirred at the same temperature for 2 h. Then, the volatiles were removed under reduced pressure (40 o C). The residue was successively treated with toluene (10 mL) and absolute EtOH (3×10 mL) and each time the solvent was removed under reduced pressure. The resulting polyol was found to be sufficiently pure by NMR and used in the next step without any further purification. ] within the lumen of the ER, cells were incubated with mag-fluo4/AM (20 µM, Life Technologies, Paisley, UK) under conditions that favor sequestration of the indicator into the ER lumen. 48 Cells were washed, permeabilized using saponin, resuspended in cytosol-like medium (CLM) supplemented with FCCP (10 μM, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) to inhibit mitochondria, and distributed into black half-area 96-well plates (Greiner Bio-One). 48 CLM had the following composition: 2 mM NaCl, 140 mM KCl, 1 mM EGTA, 20 Table S2 ). pK d values were then used for statistical analyses. 51 For comparisons of differences between pEC 50 and pK d values (pEC 50 -pK d ), the standard deviation of the difference (σ ୮େ ఱబ ି ౚ ) was calculated from the individual variances (σ ୮େ ఱబ and σ ୮ ౚ ): 52 
